Skip to main content

It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can improve outcomes in patients with cardiac anomalies, hypocalcemia, cleft palate, kidney disease, intellectual development, and schizophrenia. This webinar will review recent publications with findings that add to what is known about the diagnosis and management of 22q DS in routine practice.